NTRK2 and breast carcinoma: The primary BDNF receptor, tropomyosin kinase B (TrkB), can be a predictive marker of poor clinicopathological prognosis in breast cancer patients (Zhang et al., 2016), while preclinical studies have shown that inhibiting TrkB leads to favorable effects in neuropathic pain (Wang et al., 2009).